Warsaw, Poland – Aurora, a leading Canadian cannabis company, is set to significantly expand its presence in the Polish medical cannabis market with the introduction of two new high-potency cannabis flower varieties. The company has launched “Farm Gas” and is preparing to launch “Sourdough,” both designed to address the therapeutic needs of patients requiring elevated levels of tetrahydrocannabinol (THC).
The move underscores Aurora’s strategic focus on broadening its footprint within the burgeoning European medical cannabis sector. Poland represents a key market for expansion, and the introduction of these specific strains highlights the company’s aim to diversify the treatment options available to Polish patients under prescription.
Introducing the New Strains
The two new products are distinct in their genetic profiles and THC concentrations, offering physicians and patients additional choices within the medical cannabis framework. Both are presented as cannabis flower varieties, intended for medical use under strict regulatory guidelines in Poland.
The first variety, “Farm Gas,” became available for prescription in Poland on June 30, 2025. This strain is derived from a cross of Sour Diesel and GMO genetics, lineages known in the cannabis community for robust profiles. Farm Gas boasts a significant THC concentration of 27%, while containing less than 1% cannabidiol (CBD). This high THC-to-CBD ratio is specifically targeted at therapeutic applications where high THC levels are considered medically appropriate by prescribing physicians.
Following the launch of Farm Gas, Aurora anticipates the introduction of its second new strain, “Sourdough.” This variety is expected to become available for prescription in Poland in early August 2025. Sourdough is bred from Cake and Diesel genetics, bringing a different profile to the market. It features an even higher THC potency, recorded at 29%, and also contains less than 1% CBD. The introduction of Sourdough will further broaden the range of high-THC options available to Polish patients requiring such specific cannabinoid profiles for their treatment regimens.
Strategic Expansion in Europe
Aurora’s introduction of these high-potency strains into Poland is a clear indicator of its ongoing strategy to deepen its penetration in European medical cannabis markets. The European landscape for medical cannabis is characterized by evolving regulations and increasing patient access, presenting significant opportunities for companies like Aurora.
By bringing strains with distinct and high cannabinoid profiles to market, Aurora aims to position itself as a key provider meeting specific patient needs that may not be adequately addressed by currently available products. This targeted approach in markets such as Poland allows the company to build relationships with healthcare professionals and patient advocacy groups, fostering trust and facilitating access to cannabis-based medicines where legally permitted and medically appropriate.
Meeting Patient Needs
The decision to focus on strains with elevated THC levels, such as 27% for Farm Gas and 29% for Sourdough, is directly linked to the stated purpose of meeting the needs of patients requiring such potency for therapeutic purposes. Medical cannabis is prescribed for a variety of conditions, and the specific cannabinoid profile, particularly the concentration of THC, is a critical factor considered by physicians when determining the most appropriate treatment for an individual patient.
High-THC strains are often considered for patients dealing with conditions where pain management, appetite stimulation, or addressing spasticity are primary therapeutic goals, among others. The low CBD content in these particular strains signifies a focus on maximizing the effects associated with THC.
However, it is important to note that the suitability of any medical cannabis product, regardless of its potency, is a decision made between a patient and their prescribing physician, taking into account the patient’s specific condition, medical history, and potential interactions with other medications.
Market Impact and Future Outlook
Aurora’s expansion with these high-THC strains is expected to influence the competitive dynamics within the Polish medical cannabis market, offering more choices to patients and potentially setting a new benchmark for potency within the accessible product range. The sequential launch of Farm Gas in late June 2025 and Sourdough in early August 2025 indicates a phased market entry strategy.
This development aligns with broader trends observed globally and within Europe, where regulatory frameworks are gradually accommodating a wider range of medical cannabis products to cater to diverse patient needs. Aurora’s commitment to the Polish market, demonstrated by these new product introductions, signals its intent to be a long-term player in the region.
As the European medical cannabis sector continues to mature, the ability of companies to offer a diverse portfolio of products with varying cannabinoid profiles will be crucial. Aurora’s introduction of Farm Gas and Sourdough in Poland positions the company to capture a segment of the market requiring high-THC options, potentially paving the way for further product introductions and market expansions in the future.
